205 related articles for article (PubMed ID: 32709538)
21. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
22. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
[TBL] [Abstract][Full Text] [Related]
23. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
Nica A; Lee JYJ; Hong NL; May T
Gynecol Oncol; 2021 Jan; 160(1):206-213. PubMed ID: 33032821
[TBL] [Abstract][Full Text] [Related]
25. Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.
Marchocki Z; Tone A; Virtanen C; de Borja R; Clarke B; Brown T; May T
J Ovarian Res; 2022 May; 15(1):50. PubMed ID: 35501919
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
[TBL] [Abstract][Full Text] [Related]
27. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Silberman JN; Bercow AS; Gockley AA; Eisenhauer EL; Sisodia R; Randall T; Del Carmen MG; Goodman A; Castro CM; Melamed A; Bregar AJ
Gynecol Oncol; 2023 Aug; 175():60-65. PubMed ID: 37327540
[TBL] [Abstract][Full Text] [Related]
28. Changes in Ki-67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival.
Pölcher M; Friedrichs N; Rudlowski C; Fimmers R; Keyver-Paik MD; Kübler K; Sauerwald A; Büttner R; Kuhn W; Braun M
Int J Gynecol Cancer; 2010 May; 20(4):555-60. PubMed ID: 20442588
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Liang MI; Prendergast EN; Staples JN; Holschneider CH; Cohen JG; Cass I
J Surg Oncol; 2019 Sep; 120(4):779-785. PubMed ID: 31283034
[TBL] [Abstract][Full Text] [Related]
31. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
32. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
[TBL] [Abstract][Full Text] [Related]
33. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
[TBL] [Abstract][Full Text] [Related]
35. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
[TBL] [Abstract][Full Text] [Related]
36. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
Zhu YF; He LS; Zhang ZD; Huang QS
Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
[TBL] [Abstract][Full Text] [Related]
37. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
38. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
[TBL] [Abstract][Full Text] [Related]
39. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
Altman AD; McGee J; May T; Lane K; Lu L; Xu W; Ghatage P; Rosen B
Gynecol Oncol; 2017 Nov; 147(2):257-261. PubMed ID: 28800940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
